Developments in Biobanking Workflow Standardization Providing Samples Integrity and Stability

Research output: Contribution to journalReview article

Standard

Developments in Biobanking Workflow Standardization Providing Samples Integrity and Stability. / Malm, Johan; Fehniger, Thomas; Danmyr, Pia; Végvári, Ákos; Welinder, Charlotte; Lindberg, Henrik; Appelqvist, Roger; Sjödin, Karin; Wieslander, Elisabet; Laurell, Thomas; Hober, Sophia; Berven, Frode; Fenyö, David; Wang, Xiangdong; Andrén, Per E; Edula, Goutham; Carlsohn, Elisabet; Fuentes, Manuel; Nilsson, Carol; Dahlbäck, Magnus; Rezeli, Melinda; Erlinge, David; Marko-Varga, György.

In: Journal of Proteomics, Vol. 95, 2013, p. 38-45.

Research output: Contribution to journalReview article

Harvard

Malm, J, Fehniger, T, Danmyr, P, Végvári, Á, Welinder, C, Lindberg, H, Appelqvist, R, Sjödin, K, Wieslander, E, Laurell, T, Hober, S, Berven, F, Fenyö, D, Wang, X, Andrén, PE, Edula, G, Carlsohn, E, Fuentes, M, Nilsson, C, Dahlbäck, M, Rezeli, M, Erlinge, D & Marko-Varga, G 2013, 'Developments in Biobanking Workflow Standardization Providing Samples Integrity and Stability', Journal of Proteomics, vol. 95, pp. 38-45. https://doi.org/10.1016/j.jprot.2013.06.035

APA

CBE

MLA

Vancouver

Author

Malm, Johan ; Fehniger, Thomas ; Danmyr, Pia ; Végvári, Ákos ; Welinder, Charlotte ; Lindberg, Henrik ; Appelqvist, Roger ; Sjödin, Karin ; Wieslander, Elisabet ; Laurell, Thomas ; Hober, Sophia ; Berven, Frode ; Fenyö, David ; Wang, Xiangdong ; Andrén, Per E ; Edula, Goutham ; Carlsohn, Elisabet ; Fuentes, Manuel ; Nilsson, Carol ; Dahlbäck, Magnus ; Rezeli, Melinda ; Erlinge, David ; Marko-Varga, György. / Developments in Biobanking Workflow Standardization Providing Samples Integrity and Stability. In: Journal of Proteomics. 2013 ; Vol. 95. pp. 38-45.

RIS

TY - JOUR

T1 - Developments in Biobanking Workflow Standardization Providing Samples Integrity and Stability

AU - Malm, Johan

AU - Fehniger, Thomas

AU - Danmyr, Pia

AU - Végvári, Ákos

AU - Welinder, Charlotte

AU - Lindberg, Henrik

AU - Appelqvist, Roger

AU - Sjödin, Karin

AU - Wieslander, Elisabet

AU - Laurell, Thomas

AU - Hober, Sophia

AU - Berven, Frode

AU - Fenyö, David

AU - Wang, Xiangdong

AU - Andrén, Per E

AU - Edula, Goutham

AU - Carlsohn, Elisabet

AU - Fuentes, Manuel

AU - Nilsson, Carol

AU - Dahlbäck, Magnus

AU - Rezeli, Melinda

AU - Erlinge, David

AU - Marko-Varga, György

PY - 2013

Y1 - 2013

N2 - Recommendations and outlines for standardization in biobanking processes are presented by a research team with long-term experiences in clinical studies. These processes have important bearing on the use of samples in developing assays. These measurements are useful to document states of health and disease that are beneficial for academic research, commercial healthcare, drug development industry and government regulating agencies. There is a need for increasing awareness within proteomics and genomics communities regarding the basic concepts of collecting, storing and utilizing clinical samples. Quality control and samples suitability for analysis needs to be documented and validated to ensure data integrity and establish contexts for interpretation of results. Standardized methods in proteomics and genomics are required to be practiced throughout the community allowing datasets to be comparable and shared for analysis. For example, sample processing of thousands of clinical samples, performed in 384 high-density sample tube systems in a fully automated workflow, preserves sample content, is presented showing validation criteria. Large studies will be accompanied by biological, molecular information with corresponding clinical records from patients and healthy donors. These developments position biobanks of human patient samples as an increasingly recognized major asset in disease research, future drug development and within patient care.

AB - Recommendations and outlines for standardization in biobanking processes are presented by a research team with long-term experiences in clinical studies. These processes have important bearing on the use of samples in developing assays. These measurements are useful to document states of health and disease that are beneficial for academic research, commercial healthcare, drug development industry and government regulating agencies. There is a need for increasing awareness within proteomics and genomics communities regarding the basic concepts of collecting, storing and utilizing clinical samples. Quality control and samples suitability for analysis needs to be documented and validated to ensure data integrity and establish contexts for interpretation of results. Standardized methods in proteomics and genomics are required to be practiced throughout the community allowing datasets to be comparable and shared for analysis. For example, sample processing of thousands of clinical samples, performed in 384 high-density sample tube systems in a fully automated workflow, preserves sample content, is presented showing validation criteria. Large studies will be accompanied by biological, molecular information with corresponding clinical records from patients and healthy donors. These developments position biobanks of human patient samples as an increasingly recognized major asset in disease research, future drug development and within patient care.

KW - Biobank

KW - Proteins

KW - Antibodies

KW - Mass spectrometry

KW - Diseases

KW - Standardization

U2 - 10.1016/j.jprot.2013.06.035

DO - 10.1016/j.jprot.2013.06.035

M3 - Review article

VL - 95

SP - 38

EP - 45

JO - Journal of Proteomics

JF - Journal of Proteomics

SN - 1874-3919

ER -